Background Golimumab has shown clinical efficacy and tolerability within its clinical trial program. No systemic outcome data regarding patient-reported outcomes and health economic parameters reflecting the real world use of golimumab in Austria are currently available.
Methods Go Active is a prospective, non-interventional, multi-centre study in Austria. The impact of golimumab therapy on work productivity and activity (WPAI) and quality of life (RAQoL for RA patients, AsQoL for axSpA patients, PsAQoL for PsA patients) is assessed by using patient reported outcomes. Patients (target recruitment: n=320) are followed up to 2 years. For the current interim analysis (data cut-off: 18DEC2017) changes in the primary endpoint from baseline to month 3 were analysed in 167 patients.
Results 167 patients are included in the current analysis (74 patients with RA, 49 patients with axSpA, and 44 patients with PsA). At study entry, most patients were biological-naïve and employed.
Median age at registration was 52 years (patients with RA: 57 years, patients with axSpA: 41 years, and patients with PsA: 44 years). Almost 2/3 of patients were female (84% of patients with RA, 37% patients with axSpA, and 55% of patients with PsA). Most patients were biological-naïve at study entry (77% of all patients, 73% of patients with RA, 80% of patients with axSpA, and 82% of patients with PsA). 42% of patients were not employed (58% of patients with RA, 29% of patients with axSpA, and 30% of patients with SpA); 14% due to incapacity for work (12% of patients with RA, 21% of patients with axSpA, and 16% of patients with SpA) and 54% due to age-related pension (60% of patients with RA, 21% of patients with axSpA, and 69% of patients with SpA). Most of the patients, who worked for pay, worked full time. 159 of all patients and 66 of employed patients completed the WPAI questionnaire at baseline and after 3 months. Overall work productivity improved by −33 (−40 for patients with RA, and −31 for patients with axSpA and PsA) and activity impairment by −30 (−40 for patients with RA and axSpA, and −20 for patients with PsA; figure 1). Quality of life improved by −5 for patients with axSpA and PsA, and by −7 for patients with RA.
Conclusions This interim analysis shows that golimumab treatment is effective in improving work productivity, daily activities as well as quality of life already within the first 3 months of treatment in RA, axSpA and PsA patients.
Disclosure of Interest C. Dejaco Consultant for: Consulting fees from Merck Sharp and Dohme, Paid instructor for: Remuneration form Merck Sharp and Dohme, Speakers bureau: Merck Sharp and Dohme, T. Mueller: None declared, O. Zamani: None declared, U. Kurtz: None declared, S. Egger: None declared, J. Resch-Passini: None declared, A. Totzauer: None declared, W. Eisterer: None declared, B. Yazdani-Biuki: None declared, T. Schwingenschloegl: None declared, P. Peichl: None declared, A. Kraus: None declared, G. Naerr Employee of: Merck Sharp and Dohme Ges.m.b.H, V. Rickert Employee of: Merck Sharp and Dohme Ges.m.b.H
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.